

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT

**LUX-VALVE PLUS SELECTED FOR THE EXPERT PANEL
SCIENTIFIC ADVICE PILOT**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that, following the enrollment in the Total Product Life Cycle Advisory Program (“**TAP**”) pilot of the U.S. Food and Drug Administration (“**FDA**”), Lux-Valve Plus has been selected for the Expert Panel Scientific Advice Pilot as at the date of issuance of this announcement. The Expert Panel Scientific Advice Pilot, launched by the European Medicines Agency (“**EMA**”), aims to give scientific advice on the intended clinical development strategy and proposals for the clinical investigation of certain high-risk medical devices, as well as promote innovation and faster patient access to safer and more effective devices. The EMA is a decentralized agency of the European Union (“**EU**”) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU. The expert panels will provide advice to the Company on the clinical development strategy and/or for the clinical investigation of Lux-Valve Plus. This is expected to accelerate the clinical development and registration progress of Lux-Valve Plus for CE marking in Europe, expand the global reach and facilitate the internationalization progress of the product.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize Lux-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, October 10, 2023

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.